Adaptive Biotechnologies Corporation

NasdaqGS:ADPT Lagerbericht

Marktkapitalisierung: US$875.1m

Adaptive Biotechnologies Management

Management Kriterienprüfungen 2/4

Adaptive Biotechnologies CEO ist Chad Robins , ernannt in Sep 2009, hat eine Amtszeit von 15.17 Jahren. Die jährliche Gesamtvergütung beträgt $8.90M , bestehend aus 7.4% Gehalt und 92.6% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 1.23% der Aktien des Unternehmens, im Wert von $10.77M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.7 Jahre bzw. 8.8 Jahre.

Wichtige Informationen

Chad Robins

Geschäftsführender

US$8.9m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts7.4%
Amtszeit als Geschäftsführer15.2yrs
Eigentum des Geschäftsführers1.2%
Durchschnittliche Amtszeit des Managements5.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder8.8yrs

Jüngste Management Updates

Recent updates

Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?

Nov 01
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?

Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher

Oct 05
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Jul 12
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

May 08
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Apr 03
It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Adaptive Biotechnologies: A Post Earnings Assessment

Feb 25

Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Feb 17
Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%

Feb 01
Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%

Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be

Nov 17
Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Oct 13
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Jul 06
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding

May 05
Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding

We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

Apr 15
We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Dec 13
Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system

Oct 11

Adaptive Biotechnologies announces $250M non-dilutive royalty financing

Sep 12

We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate

Aug 14
We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate

Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth

Apr 29
Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth

Adaptive Biotechnologies: Good Buy For Long-Term Investors

Apr 15

Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?

Feb 26
Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?

We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth

Jan 09
We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Chad Robins im Vergleich zu den Einnahmen von Adaptive Biotechnologies verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

-US$195m

Jun 30 2024n/an/a

-US$213m

Mar 31 2024n/an/a

-US$215m

Dec 31 2023US$9mUS$663k

-US$225m

Sep 30 2023n/an/a

-US$196m

Jun 30 2023n/an/a

-US$191m

Mar 31 2023n/an/a

-US$195m

Dec 31 2022US$9mUS$658k

-US$200m

Sep 30 2022n/an/a

-US$221m

Jun 30 2022n/an/a

-US$232m

Mar 31 2022n/an/a

-US$229m

Dec 31 2021US$9mUS$639k

-US$207m

Sep 30 2021n/an/a

-US$190m

Jun 30 2021n/an/a

-US$171m

Mar 31 2021n/an/a

-US$155m

Dec 31 2020US$7mUS$597k

-US$146m

Sep 30 2020n/an/a

-US$122m

Jun 30 2020n/an/a

-US$99m

Mar 31 2020n/an/a

-US$82m

Dec 31 2019US$3mUS$493k

-US$70m

Sep 30 2019n/an/a

-US$62m

Jun 30 2019n/an/a

-US$56m

Mar 31 2019n/an/a

-US$53m

Dec 31 2018US$3mUS$423k

-US$46m

Vergütung im Vergleich zum Markt: ChadDie Gesamtvergütung ($USD8.90M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD3.14M).

Entschädigung vs. Einkommen: ChadDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Chad Robins (49 yo)

15.2yrs

Amtszeit

US$8,904,267

Vergütung

Mr. Chad M. Robins, M.B.A., serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He serves as an Independent Director at ARYA Sciences Acquisition Corp II since June 2020. He c...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Chad Robins
Co-Founder15.2yrsUS$8.90m1.23%
$ 10.8m
Julie Rubinstein
President & COO6.8yrsUS$2.97m0.32%
$ 2.8m
Harlan Robins
Co-Founder & Chief Scientific Officer15.2yrsUS$8.61m0.69%
$ 6.1m
Sharon Benzeno
Chief Commercial Officer of Immune Medicine6.8yrsUS$2.88m0.22%
$ 1.9m
Christopher Carlson
Founderno datakeine Datenkeine Daten
Kyle Piskel
VP, CFO & Principal Accounting Officer3.1yrsUS$1.66m0.10%
$ 916.6k
Karina Calzadilla
Vice President of Investor Relationsno datakeine Datenkeine Daten
Stacy Taylor
Senior VP5.7yrskeine Daten0.094%
$ 826.4k
Francis Lo
Chief People Officer5.6yrskeine Daten0.17%
$ 1.5m
Susan Bobulsky
Chief Commercial Officer of MRD4.3yrskeine Daten0.17%
$ 1.5m
Mary Lancelotta
Senior Vice President of MRD BioPharma1.2yrskeine Datenkeine Daten

5.7yrs

Durchschnittliche Betriebszugehörigkeit

49.5yo

Durchschnittliches Alter

Erfahrenes Management: ADPTDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.7 ).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Chad Robins
Co-Founder15.2yrsUS$8.90m1.23%
$ 10.8m
Peter Neupert
Lead Independent Director10.9yrsUS$355.00k0.093%
$ 818.2k
H. Parker
Member of Corporate Advisory Boardno datakeine Datenkeine Daten
Michelle Griffin
Independent Director5.7yrsUS$330.00k0.035%
$ 308.1k
Robert Hershberg
Independent Director11.8yrsUS$325.00k0.051%
$ 450.5k
Michael Pellini
Independent Director6.8yrsUS$310.00k0.037%
$ 322.0k
Carol Gallagher
Member of Corporate Advisory Boardno datakeine Datenkeine Daten
Craig Weissman
Member of Corporate Advisory Boardno datakeine Datenkeine Daten
Graham Allen
Member of Corporate Advisory Boardno datakeine Datenkeine Daten
Matthew Kahn
Member of Corporate Advisory Boardno datakeine Datenkeine Daten
Katey Owen
Independent Director3.7yrsUS$310.00k0.038%
$ 332.8k

8.8yrs

Durchschnittliche Betriebszugehörigkeit

58.5yo

Durchschnittliches Alter

Erfahrener Vorstand: ADPTDie Vorstandsmitglieder gelten als erfahren (8.8 Jahre durchschnittliche Amtszeit).